Could the Propionic Acid Treatment in Combination with Metformin be Safe for the Small Intestine of Diabetic Rats?
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Effects of propionic acid (PA) on the cellular and molecular processes in the small intestine under type 2 diabetes mellitus (T2DM)-induced endoplasmic reticulum (ER) stress remain incompletely studied.
OBJECTIVES: The aim of the study was to assess the state of unfolded protein response (UPR) system in the small intestine of diabetic rats and to explore PA's influence on metformin treatment.
METHODS: Male Wistar rats were divided into 1) control and 2) T2DM groups, and groups receiving (14 days, orally) 3) metformin (60 mg/kg), 4) PA (60 mg/kg), and 5) PA+metformin. Western blotting, RT-PCR, and transmission electron microscopy were performed.
RESULTS: We found that T2DM induced elevation of ER intermembrane space and UPR overactivation based on increased GRP78, ATF6 and PERK levels in small intestine. Metformin treatment led to a further UPR activation. PA supplementation partially restored enterocytes functioning via normalization of ATF6 and PERK content, while IRE1 level reached the maximum value, compared to all groups. The most pronounced effect of adaptation to the T2DMinduced ER stress was observed after combined metformin and PA action. In particular, decreased ER intermembrane space in enterocytes was detected compared to separate metformin and PA administration, which was accompanied by restored GRP78, PERK and IRE1 levels.
CONCLUSION: Our study proves the safety of additional therapy with propionic acid in combination with metformin for the functional state of small intestine. Due to its ability to modulate UPR signaling, PA may be considered a safe and perspective candidate for supportive therapy in T2DM, especially for neuroprotection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders drug targets - (2024) vom: 23. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Natrus, Larysa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diabetic intestinal complications |
|---|
| Anmerkungen: |
Date Revised 24.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0118715303273125231121062111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367558084 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367558084 | ||
| 003 | DE-627 | ||
| 005 | 20240124232256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240124s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118715303273125231121062111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM367558084 | ||
| 035 | |a (NLM)38265384 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Natrus, Larysa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Could the Propionic Acid Treatment in Combination with Metformin be Safe for the Small Intestine of Diabetic Rats? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Effects of propionic acid (PA) on the cellular and molecular processes in the small intestine under type 2 diabetes mellitus (T2DM)-induced endoplasmic reticulum (ER) stress remain incompletely studied | ||
| 520 | |a OBJECTIVES: The aim of the study was to assess the state of unfolded protein response (UPR) system in the small intestine of diabetic rats and to explore PA's influence on metformin treatment | ||
| 520 | |a METHODS: Male Wistar rats were divided into 1) control and 2) T2DM groups, and groups receiving (14 days, orally) 3) metformin (60 mg/kg), 4) PA (60 mg/kg), and 5) PA+metformin. Western blotting, RT-PCR, and transmission electron microscopy were performed | ||
| 520 | |a RESULTS: We found that T2DM induced elevation of ER intermembrane space and UPR overactivation based on increased GRP78, ATF6 and PERK levels in small intestine. Metformin treatment led to a further UPR activation. PA supplementation partially restored enterocytes functioning via normalization of ATF6 and PERK content, while IRE1 level reached the maximum value, compared to all groups. The most pronounced effect of adaptation to the T2DMinduced ER stress was observed after combined metformin and PA action. In particular, decreased ER intermembrane space in enterocytes was detected compared to separate metformin and PA administration, which was accompanied by restored GRP78, PERK and IRE1 levels | ||
| 520 | |a CONCLUSION: Our study proves the safety of additional therapy with propionic acid in combination with metformin for the functional state of small intestine. Due to its ability to modulate UPR signaling, PA may be considered a safe and perspective candidate for supportive therapy in T2DM, especially for neuroprotection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a diabetic intestinal complications | |
| 650 | 4 | |a endoplasmic reticulum stress | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a propionic acid | |
| 650 | 4 | |a small intestine | |
| 650 | 4 | |a type 2 diabetes mellitus | |
| 650 | 4 | |a unfolded protein response | |
| 700 | 1 | |a Lisakovska, Olha |e verfasserin |4 aut | |
| 700 | 1 | |a Smirnov, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Osadchuk, Yuliia |e verfasserin |4 aut | |
| 700 | 1 | |a Savosko, Serhyi |e verfasserin |4 aut | |
| 700 | 1 | |a Klys, Yuliia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders drug targets |d 2006 |g (2024) vom: 23. Jan. |w (DE-627)NLM161976174 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715303273125231121062111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 01 | ||